Sign up
Pharma Capital

Alliance Pharma receives Irish green light for nausea drug

Xonvea will be prescribed to women who are sick during pregnancy where conservative treatment has failed
pregnant woman
The drug will go on sale in Ireland towards the end of the year

Alliance Pharma PLC (LON:APH) has confirmed its morning sickness treatment Xonvea has received marketing approval in Ireland.

This paves the way for the first launch of the product outside the UK. The company to start selling the drug in the Republic in the final quarter of this year.

As in the UK, it will be prescribed for nausea and vomiting in pregnancy where conservative management has failed.

The condition affects 70-80% of women during pregnancy in Ireland, mirroring what is seen in Britain.

View full APH profile View Profile
Newswire

Alliance Pharma posts 2018 revenue surge

View All

Related Articles

lung x-ray
The company has been developing a treatment for chronic lung disease in-house and has partnered with an Australian group to develop a drug for rare liver and lung complaints

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.